Avatrombopag

Avatrombopag is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in adult patients who are to undergo a planned medical or dental procedure. It was approved by the Food and Drug Administration in May 21, 2018. Avatrombopag is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in adult patients who are to undergo a planned medical or dental procedure. It was approved by the Food and Drug Administration in May 21, 2018.